Normosang (Human Hemin)

Human Hemin supplies heme directly to the liver, which feeds back to inhibit δ‑aminolevulinic acid synthase, the first enzyme in the heme biosynthetic pathway. This feedback reduces the buildup of neurotoxic intermediates that cause the clinical manifestations of an acute porphyria attack.

The specific dose and infusion schedule of Normosang are determined by the prescribing physician based on the severity of the attack, patient weight, and clinical response. Dosing is individualized and should follow the guidance of a qualified healthcare professional.

Safety data for Human Hemin in pregnancy and lactation are limited, and the product is classified as pregnancy category unknown. Use during pregnancy or while breastfeeding should only occur if the potential benefit justifies any potential risk, and it must be decided by the treating physician.

To order Normosang, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The team then replies with pricing, availability, shipping details (including cold‑chain handling if needed) and any required import documentation.

Normosang (Human Hemin) is the primary heme‑based antidote for acute porphyria attacks, directly targeting the metabolic pathway. Alternative therapies, such as glucose loading, aim to suppress the pathway indirectly, while other agents like givosiran target specific enzymes. Hemin provides rapid symptom control, whereas alternatives may have slower onset or different safety profiles.

Normosang should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. The lyophilized powder must be reconstituted with the supplied diluent immediately before intravenous administration, and any unused solution should be discarded according to local regulations.

Normosang is supplied as a lyophilized powder for reconstitution into an injectable solution. After proper reconstitution, it is administered intravenously over a prescribed period, typically under continuous monitoring in a clinical setting to observe for infusion‑related reactions.

The most serious risks include severe allergic reactions such as anaphylaxis, hemolysis (particularly in patients with G6PD deficiency), acute renal impairment, and significant hypotension. Prompt recognition and management of these events are essential, and patients should be monitored closely during and after infusion.

Normosang should be avoided in patients with known hypersensitivity to hemin or any component of the formulation, and it is contraindicated in individuals with severe G6PD deficiency due to the risk of hemolysis. Use is also not recommended without specialist supervision in patients lacking a clear indication for heme therapy.